These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30544059)

  • 21. Divergent Long-Term Detection Rates of Proximal and Distal Advanced Neoplasia in Fecal Immunochemical Test Screening Programs: A Retrospective Cohort Study.
    Zorzi M; Hassan C; Capodaglio G; Narne E; Turrin A; Baracco M; Dal Cin A; Fiore A; Martin G; Repici A; Rex D; Rugge M
    Ann Intern Med; 2018 Nov; 169(9):602-609. PubMed ID: 30285055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A quantitative immunochemical fecal occult blood test for colorectal neoplasia.
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Ann Intern Med; 2007 Feb; 146(4):244-55. PubMed ID: 17310048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
    Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives.
    Ribbing Wilén H; Blom J; Höijer J; Andersson G; Löwbeer C; Hultcrantz R
    Scand J Gastroenterol; 2019 Mar; 54(3):303-310. PubMed ID: 30907196
    [No Abstract]   [Full Text] [Related]  

  • 25. Positive predictive values of fecal immunochemical tests used in the STOP CRC pragmatic trial.
    Nielson CM; Petrik AF; Jacob L; Vollmer WM; Keast EM; Schneider JL; Rivelli JS; Kapka TJ; Meenan RT; Mummadi RR; Green BB; Coronado GD
    Cancer Med; 2018 Sep; 7(9):4781-4790. PubMed ID: 30101513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.
    Toes-Zoutendijk E; van Leerdam ME; Dekker E; van Hees F; Penning C; Nagtegaal I; van der Meulen MP; van Vuuren AJ; Kuipers EJ; Bonfrer JMG; Biermann K; Thomeer MGJ; van Veldhuizen H; Kroep S; van Ballegooijen M; Meijer GA; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I;
    Gastroenterology; 2017 Mar; 152(4):767-775.e2. PubMed ID: 27890769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantile-based fecal hemoglobin concentration for assessing colorectal neoplasms with 1,263,717 Taiwanese screenees.
    Peng SM; Chiu HM; Jen HH; Hsu CY; Chen SL; Chiu SY; Yen AM; Fann JC; Lee YC; Chen HH
    BMC Med Inform Decis Mak; 2019 May; 19(1):94. PubMed ID: 31046760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combination of clinical risk stratification and fecal immunochemical test is useful for identifying persons with high priority of early colonoscopy.
    Jung YS; Park CH; Kim NH; Park JH; Park DI; Sohn CI
    Dig Liver Dis; 2018 Mar; 50(3):254-259. PubMed ID: 29198569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colorectal cancer screening with the fecal immunochemical test in persons aged 30 to 49 years: focusing on the age for commencing screening.
    Jung YS; Park CH; Kim NH; Park JH; Park DI; Sohn CI
    Gastrointest Endosc; 2017 Nov; 86(5):892-899. PubMed ID: 28385585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort.
    Chen LS; Yen AM; Chiu SY; Liao CS; Chen HH
    Lancet Oncol; 2011 Jun; 12(6):551-8. PubMed ID: 21592859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study).
    Wong G; Hope RL; Howard K; Chapman JR; Castells A; Roger SD; Bourke MJ; Macaskill P; Turner R; Williams G; Lim WH; Lok CE; Diekmann F; Cross NB; Sen S; Allen RDM; Chadban SJ; Pollock CA; Tong A; Teixeira-Pinto A; Yang JYH; Williams N; Au EHK; Kieu A; James L; Craig JC
    J Am Soc Nephrol; 2019 Jun; 30(6):1061-1072. PubMed ID: 31040191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening.
    Alvarez-Urturi C; Andreu M; Hernandez C; Perez-Riquelme F; Carballo F; Ono A; Cruzado J; Cubiella J; Hernandez V; Mao CG; Perez E; Salas D; Andrés M; Bujanda L; Portillo I; Sarasqueta C; Quintero E; Morillas JD; Lanas A; Sostres C; Augé JM; Castells A; Bessa X;
    Dig Liver Dis; 2016 May; 48(5):542-551. PubMed ID: 26936343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of the severity of colorectal lesion by fecal hemoglobin concentration observed during previous test in the French screening program.
    Balamou C; Koïvogui A; Rodrigue CM; Clerc A; Piccotti C; Deloraine A; Exbrayat C
    World J Gastroenterol; 2021 Aug; 27(31):5272-5287. PubMed ID: 34497450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
    Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?
    Haug U; Grobbee EJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
    Gut; 2017 Jul; 66(7):1262-1267. PubMed ID: 27006184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients.
    Vasilyev S; Smirnova E; Popov D; Semenov A; Eklund C; Hendolin P; Paloheimo L; Syrjänen K
    Anticancer Res; 2015 May; 35(5):2873-80. PubMed ID: 25964570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.